首页> 美国卫生研究院文献>Fukushima Journal of Medical Science >Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2-40 monoclonal antibody in breast cancer
【2h】

Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2-40 monoclonal antibody in breast cancer

机译:免疫组织化学D2-40单克隆抗体在乳腺癌中检测淋巴管生成的临床病理学意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To elucidate the association between the lymphangiogenesis and clinicopathological factors including the survival in breast cancer, 91 Japanese patients with breast cancer were investigated. The lymphangiogenesis was evaluated by the count of lymph vessel density (LVD) with immunohistochemical method using D2-40 monoclonal antibody, a specific marker for lymphatic endothelial cells.D2-40-positive lymph vessels were detected in 87 of 91 cases, and were mainly distributed in the peritumoral lesions or around the tumor edge. There was a significant difference in disease-free survival (DFS) and overall survival (OS) between patients with high LVD and with low LVD (p=0.02, 0.01, respectively, log-rank test). In addition, LVD significantly correlated with the following clinicopathological factors: menopausal status (p<0.01), tumor size (p<0.01), lymph-node status (p=0.01) lymphatic vessel invasion (LVI) (p<0.01), blood vessel invasion (BVI) (p=0.03) and estrogen receptor status (ER) (p=0.02).Those data suggest that D2-40 monoclonal antibody is a useful marker for evaluating the LVD and its evaluation is helpful to predict the survival in breast cancer.
机译:为了阐明淋巴管生成与临床病理因素之间的关联,包括乳腺癌的存活率,对91名日本乳腺癌患者进行了调查。采用淋巴管内皮细胞特异性标记物D2-40单克隆抗体通过免疫组织化学方法对淋巴管密度(LVD)进行计数来评估淋巴管生成.91例患者中有87例检测到D2-40阳性淋巴管分布于肿瘤周围的病灶或肿瘤边缘周围。高LVD和低LVD的患者的无病生存期(DFS)和总生存期(OS)有显着差异(p = 0.02,对数秩检验分别为0.01)。此外,LVD与以下临床病理因素显着相关:更年期状态(p <0.01),肿瘤大小(p <0.01),淋巴结状态(p = 0.01)淋巴管浸润(LVI)(p <0.01),血液血管浸润(BVI)(p = 0.03)和雌激素受体状态(ER)(p = 0.02)。这些数据表明D2-40单克隆抗体是评估LVD的有用标志物,其评估有助于预测LVD的存活率。乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号